1. Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care. (3rd September 2018) Authors: Glintborg, B; Kringelbach, T; Bolstad, N; Warren, DJ; Eng, G; Sørensen, IJ; Loft, AG; Hendricks, O; Hansen, IMJ; Linauskas, A; Nordin, H; Kristensen, S; Lindegaard, H; Jensen, DV; Goll, GL; Høgdall, E; Gehin, J; Enevold, C; Nielsen, CH; Krogh, NS Journal: Scandinavian journal of rheumatology Issue: Volume 47:Number 5(2018) Page Start: 418 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study. (2nd November 2021) Authors: Gehin, JE; Warren, DJ; Syversen, SW; Lie, E; Sexton, J; Loli, L; Wierød, A; Bjøro, T; Kvien, TK; Bolstad, N; Goll, GL Journal: Scandinavian journal of rheumatology Issue: Volume 50:Number 6(2021) Page Start: 445 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0700 Immunogenicity in patients switching from stable originator infliximab treatment to CT-P13: analyses across six diseases from the 52-week randomized nor-switch study. (15th June 2017) Authors: Goll, GL; Olsen, IC; Lundin, KEA; Jørgensen, KK; Lorentzen, M; Klaasen, RA; Warren, DJ; Mørk, C; Jahnsen, J; Haavardsholm, EA; Kvien, TK; Bolstad, N Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 472 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗